Testosterone therapy heart safety has been one of the most hotly argued questions in men’s medicine for more than a decade, and in 2025 the ground shifted. The U.S. Food and Drug Administration removed the long-standing boxed warning that linked testosterone products to increased cardiovascular risk, pointing to the large TRAVERSE clinical trial and follow-up blood-pressure studies. Below we break down exactly what the FDA changed, what the science actually found, and what it means if you are weighing treatment for low testosterone.
For years, that black-box warning sat at the top of every testosterone label and shaped how cautiously doctors and patients approached therapy. Its removal does not mean testosterone is risk-free, but it does reflect the strongest evidence yet gathered on the question.
What the 2025 FDA Testosterone Update Changed
In February 2025, the FDA issued class-wide labeling changes for all testosterone products. The headline: language in the boxed warning describing a possible increase in heart attacks and strokes was removed. In its place, the agency added clearer guidance on a more measurable concern, blood pressure. Products that completed ambulatory blood-pressure monitoring studies now carry specific information about a possible rise in blood pressure, and those that have not are getting a new blood-pressure warning.
In plain terms, the FDA swapped a broad, poorly supported cardiovascular alarm for a narrower, better-documented caution. That distinction matters for anyone researching testosterone therapy heart safety, because it changes the conversation from “does this cause heart attacks?” to “how do we monitor it responsibly?”
Inside the TRAVERSE Trial
The decision rested largely on TRAVERSE, the largest cardiovascular safety study of testosterone ever run. Researchers enrolled 5,246 men aged 45 to 80 who had symptoms of low testosterone from hypogonadism along with existing heart disease or a high risk of it. Half received a daily testosterone gel and half a placebo, and they were followed for a mean of roughly 33 months.
The result: testosterone was no more likely than placebo to trigger major cardiac events, defined as cardiovascular death, non-fatal heart attack, or non-fatal stroke. Published in the New England Journal of Medicine in 2023, the trial finally gave regulators the high-quality data they had been missing when the original warning was written.
What Testosterone Therapy Heart Safety Really Means
Reassuring as the headline is, TRAVERSE came with fine print worth understanding. Men on testosterone showed slightly higher rates of a few specific problems: irregular heart rhythms such as atrial fibrillation, blood clots in the lungs, and acute kidney injury. Average systolic blood pressure also nudged upward, a small shift, but enough that the FDA singled it out.
That is why how testosterone can affect blood pressure deserves real attention, and why lab values like your hematocrit level should be tracked during treatment. Testosterone therapy heart safety is best understood as manageable with monitoring, not as nothing to watch. The removal of the boxed warning reflects that the feared population-wide heart risk did not materialize, not that testosterone is a casual supplement.
Who Should Consider Treatment and How Monitoring Works
The FDA update applies to men with a genuine medical need: diagnosed low testosterone confirmed by blood tests and symptoms. It is not an endorsement of testosterone for healthy men chasing extra energy or muscle. If you are noticing the common signs of low testosterone, such as persistent fatigue, low libido, mood changes, or loss of strength, the right first step is a proper evaluation rather than self-treatment.
A responsible program starts with baseline labs and a review of your heart health, then rechecks testosterone, hematocrit, and blood pressure at regular intervals. That process is also how a clinician decides whether testosterone therapy is a good idea for you in the first place. Careful monitoring is exactly what turns the TRAVERSE findings into real-world safety.
The Bottom Line
The 2025 FDA reversal is a meaningful vote of confidence in testosterone therapy heart safety for men who genuinely need treatment, backed by the best trial evidence available. It also keeps a sensible guardrail in place around blood pressure and routine follow-up. If low testosterone is affecting your daily life, the team at Nova Men’s Health can evaluate your levels, review your cardiovascular history, and build a monitored plan tailored to you. Book a consultation today to talk through your options with experienced clinicians.
What This Means for Current Patients
If you are already on testosterone therapy, this label change is not a reason to stop or adjust your dose on your own. It simply means the regulatory guidance now lines up with what large-scale evidence actually shows. Keep your scheduled follow-ups, monitor your blood pressure at home if your provider recommends it, and report symptoms such as chest discomfort, palpitations, or swelling in your legs without delay. For men considering therapy for the first time, the update strips away a layer of fear that was never well supported, while reinforcing an important truth: testosterone is a prescription treatment that deserves ongoing medical oversight, not a shortcut to be taken lightly.
This article is for general education and is not medical advice. Always consult a qualified healthcare provider about your individual health and any treatment decisions.